Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 24 studies | 30% ± 11% | |
classical monocyte | 15 studies | 32% ± 11% | |
endothelial cell | 14 studies | 28% ± 12% | |
monocyte | 13 studies | 34% ± 15% | |
conventional dendritic cell | 13 studies | 27% ± 7% | |
basal cell | 11 studies | 31% ± 11% | |
endothelial cell of vascular tree | 9 studies | 24% ± 7% | |
type I pneumocyte | 7 studies | 32% ± 18% | |
non-classical monocyte | 7 studies | 25% ± 6% | |
myeloid cell | 7 studies | 34% ± 7% | |
dendritic cell | 6 studies | 29% ± 11% | |
epithelial cell | 6 studies | 30% ± 12% | |
alveolar macrophage | 5 studies | 32% ± 12% | |
mononuclear phagocyte | 3 studies | 24% ± 4% | |
enterocyte | 3 studies | 22% ± 5% | |
secretory cell | 3 studies | 32% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 99% | 2545.83 | 355 / 359 | 97% | 32.91 | 277 / 286 |
lung | 100% | 5148.20 | 576 / 578 | 92% | 38.95 | 1066 / 1155 |
brain | 87% | 996.30 | 2301 / 2642 | 97% | 26.66 | 685 / 705 |
thymus | 95% | 2004.50 | 622 / 653 | 87% | 62.10 | 526 / 605 |
prostate | 93% | 1445.07 | 229 / 245 | 88% | 24.09 | 441 / 502 |
esophagus | 85% | 2279.49 | 1228 / 1445 | 96% | 44.32 | 176 / 183 |
intestine | 83% | 1275.94 | 800 / 966 | 98% | 40.20 | 518 / 527 |
breast | 96% | 3273.46 | 441 / 459 | 70% | 11.75 | 787 / 1118 |
uterus | 77% | 1449.93 | 131 / 170 | 84% | 33.55 | 385 / 459 |
bladder | 71% | 1320.67 | 15 / 21 | 89% | 33.63 | 451 / 504 |
skin | 70% | 1246.16 | 1263 / 1809 | 87% | 24.34 | 410 / 472 |
kidney | 79% | 861.03 | 70 / 89 | 77% | 19.96 | 692 / 901 |
adrenal gland | 47% | 471.51 | 122 / 258 | 76% | 28.11 | 174 / 230 |
pancreas | 11% | 87.97 | 37 / 328 | 98% | 43.29 | 175 / 178 |
ovary | 37% | 424.22 | 66 / 180 | 65% | 10.86 | 278 / 430 |
adipose | 99% | 5748.52 | 1189 / 1204 | 0% | 0 | 0 / 0 |
heart | 97% | 2455.74 | 839 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 37.29 | 43 / 45 |
muscle | 93% | 1464.89 | 749 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 84% | 1566.54 | 1120 / 1335 | 0% | 0 | 0 / 0 |
spleen | 61% | 628.63 | 147 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 45% | 18.80 | 13 / 29 |
liver | 8% | 88.72 | 19 / 226 | 31% | 4.83 | 127 / 406 |
peripheral blood | 39% | 591.32 | 358 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 29% | 3.06 | 23 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030307 | Biological process | positive regulation of cell growth |
GO_0051545 | Biological process | negative regulation of elastin biosynthetic process |
GO_0048661 | Biological process | positive regulation of smooth muscle cell proliferation |
GO_0007165 | Biological process | signal transduction |
GO_0038134 | Biological process | ERBB2-EGFR signaling pathway |
GO_0050731 | Biological process | positive regulation of peptidyl-tyrosine phosphorylation |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0051549 | Biological process | positive regulation of keratinocyte migration |
GO_0007517 | Biological process | muscle organ development |
GO_0007173 | Biological process | epidermal growth factor receptor signaling pathway |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0038135 | Biological process | ERBB2-ERBB4 signaling pathway |
GO_0035313 | Biological process | wound healing, spreading of epidermal cells |
GO_0008016 | Biological process | regulation of heart contraction |
GO_0060326 | Biological process | cell chemotaxis |
GO_0090303 | Biological process | positive regulation of wound healing |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0030666 | Cellular component | endocytic vesicle membrane |
GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
GO_0009986 | Cellular component | cell surface |
GO_0008201 | Molecular function | heparin binding |
GO_0048018 | Molecular function | receptor ligand activity |
GO_0005154 | Molecular function | epidermal growth factor receptor binding |
GO_0008083 | Molecular function | growth factor activity |
GO_0005515 | Molecular function | protein binding |
GO_0030297 | Molecular function | transmembrane receptor protein tyrosine kinase activator activity |
Gene name | HBEGF |
Protein name | Proheparin-binding EGF-like growth factor [Cleaved into: Heparin-binding EGF-like growth factor (HB-EGF) (HBEGF) (Diphtheria toxin receptor) (DT-R)] Short form heparin-binding EGF-like growth factor |
Synonyms | DTS HEGFL DTR |
Description | FUNCTION: Growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. Required for normal cardiac valve formation and normal heart function. Promotes smooth muscle cell proliferation. May be involved in macrophage-mediated cellular proliferation. It is mitogenic for fibroblasts, but not endothelial cells. It is able to bind EGF receptor/EGFR with higher affinity than EGF itself and is a far more potent mitogen for smooth muscle cells than EGF. Also acts as a diphtheria toxin receptor. |
Accessions | Q99075 ENST00000230990.7 Q1HK36 |